Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 43

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
 under the rules of Nasdaq. In a concurrent private placement, we also issued to the
February 2025 Purchasers unregistered warrants (the “February 2025 Warrants”) to purchase up to an aggregate of 300,700 shares
of common stock at an exercise price of $2.95 per share. The February 2025 Warrants are exercisable upon issuance and expire twenty-four
months from the date of issuance.

The shares were offered pursuant to a “shelf”
registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission
(the “SEC”) on July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February
6, 2025 and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

The Placement Agent acted as our exclusive placement
agent in connection with the offering. Pursuant to the terms of the placement agent agreement, we paid the Placement Agent a cash transaction
fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management fee equal to 1.0% of the aggregate gross cash
proceeds in the offering. In addition, we paid for certain non-accountable expenses in the amount of $15,000 and a clearing fee in the
amount of $10,000. We also issued to the Placement Agent (or its designees) warrants to purchase up to 22,554 shares of Common Stock (the
“February 2025 Placement Agent Warrants”). The February 2025 Placement Agent Warrants have an exercise price equal to $4.469
per share and are exercisable upon issuance and expire twenty-four months from the date of issuance.

The registered direct offering and the concurrent
private placement (collectively, the “February 2025 Offering”) closed on February 6, 2025, resulting in net proceeds of approximately
$908,627, after deducting estimated offering expenses paid by us, including the Placement Agent fees.

Pursuant to the February 2025 Securities Purchase
Agreement, within 45 days from the date of the February 2025 Securities Purchase Agreement, we were required to file a registration statement
with the SEC providing for the resale by the February 2025 Purchasers of the shares of common stock issuable upon exercise of the February
2025 W